Abstract
The purpose of this study was to determine the maximum tolerated dose of carboplatin administered with 500 mg/m2 thiotepa and 100 mg/m2melphalan followed by autologous peripheral blood stem cell (PBSC) infusion in patients with refractory malignancies. Twenty-eight patients with refractory malignancies received high-dose thiotepa (500 mg/m2, melphalan (100 mg/m2) and escalating doses of carboplatin 900–1500 mg/m2) followed by infusion of cryopreserved autologous PBSCs. The maximum tolerated doses were determined to be 500 mg/m2 thiotepa, 100 mg/m2 melphalan and 1350 mg/m2 carboplatin. Two consecutive patients receiving 1500 mg/m2 carboplatin experienced grade 3 mucositis and colitis. Ten patients were enrolled at the maximum tolerated dose and none had grade 3–4 regimen-related toxicity and mortality. All patients at this level experienced grade 1–2 mucositis, 90% grade 1–2 gastrointestinal toxicity, 30% grade 1–2 cardiac and renal toxicity, and 10% experienced grade 1 hepatic toxicity. The median time to achieve a granulocyte count of 0.5 × 109/l was 9 days (range 7–12 days) and platelet count of 20 × 109/l was 10 days (range 7–15 days). Of eight patients with stage IV refractory breast cancer, even were evaluable for response, one patient on day 75 will be evaluated soon. Five of seven (71.5%) evaluable patients achieved a complete remission (CR) and two had no response. Of seven patients with non-Hodgkin's lymphoma (n = 4) or Hodgkin's disease (n = 3), five achieved a CR (71.5%). Thiotepa, melphalan and carboplatin can be administered in high doses with tolerable mucositis as the major side-effect. This combination has significant activity in patients with breast cancer, and phase II studies in patients with breast cancer and other chemotherapy-sensitive malignancies are warranted. Bone Marrow Transplantation (2000) 25 , 697–703.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle J Clin Oncol 1990 8: 638–647
Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation (ABMT) for acute leukemia in remission: an analysis of 1322 cases Bone Marrow Transplant 1989 4: (Suppl.2) 3–5
Eder JP, Elias A, Shea TC et al. A phase I–II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients J Clin Oncol 1990 8: 1239–1245
Moormeier JA, Williams SF, Kaminer LS et al. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies J Natl Cancer Inst 1990 82: 29–34
Eder JP, Antman K, Elias A et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors J Natl Cancer Inst 1988 80: 1221–1226
Williams SF, Bitran JD, Kaminer L et al. A phase I–II study of bialkylator chemotherapy, high-dose thiotepa and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer J Clin Oncol 1987 5: 260–265
Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer J Clin Oncol 1986 4: 1592–1597
Stiff PJ, McKenzie RS, Albert DS et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma J Clin Oncol 1994 12: 176–183
Antman K, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879
Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan, and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer Bone Marrow Transplant 1996 17: 769–774
Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 1988 6: 1368–1376
Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer J Clin Oncol 1989 7: 1824–1830
Holmberg LA, Demirer T, Rowley S et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III–IV ovarian cancer Bone Marrow Transplant 1998 22: 651–659
Ozols RF, Ihde DC, Linehan M et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ cell tumors J Clin Oncol 1988 6: 1031–1040
Lazarus HM, Reed MD, Spitzer TR et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer Cancer Treat Rep 1987 71: 689–695
Wolff SN, Herzig RH, Fay JW et al. High-dose N, N′, N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies Semin Oncol 1990 17: 2–6
Lazarus HM, Herzig RH, Graham-Pole J et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer J Clin Oncol 1983 1: 359–367
Demirer T, Petersen FB, Bensinger WI et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte-colony stimulating factor in patients with acute myelogenous leukemia Bone Marrow Transplant 1996 18: 29–34
Sarosy G, Leyland-Jones B, Soochan P et al. The systemic administration of intravenous melphalan J Clin Oncol 1988 6: 1768–1782
Wright JC, Golomb FM, Gumport SL et al. Summary of results with triethylenethiophosphoramide Ann NY Acad Sci 1958 68: 937–966
Farber S, Appleton R, Downing V et al. Clinical studies on the carcinolytic action of triethylenephosphoramide Cancer 1953 6: 135–141
Lemaistre CF, Herzig GP, Herzig RH et al. High-dose thiotepa and autologous bone marrow rescue for the treatment of breast cancer Breast Cancer Res Treat 1987 10: 89–94
Maranichi D, Piana L, Blaise D et al. Phase I–II studies of high-dose alkylating agents in poor risk patients with breast cancer with autologous bone marrow transplant. In: Dicke K, Spitzer TR, Jagannath S (eds) ABMT: Proceedings of the 3rd international symposium University of Texas MD Anderson Hospital: Houston, TX 1987 475–480
Corringham R, Gilmore M, Prentice H et al. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors Cancer 1983 52: 1783–1787
Bateman JC . Chemotherapy of solid tumors with triethylene thiophosphamide New Engl J Med 1955 252: 879–887
Ultmann JE, Hyman GA, Crandall C et al. Triethylenephosphoramide (thiotepa) in the treatment of neoplastic disease Cancer 1957 10: 902–911
Ozols RF, Behrens BC, Ostchega Y et al. High-dose cisplatin and high-dose carboplatin in refractory ovarian cancer Cancer Treatment Rev 1985 12: 59–62
Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support J Clin Oncol 1989 7: 651–655
Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 1992 10: 102–110
Holland K, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care J Clin Oncol 1996 14: 1156–1164
Ayash L, Elias A, Ibrahim J et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma J Clin Oncol 1998 16: 1000–1007
Demirer T, Buckner CD, Bensinger WI et al. Peripheral blood stem cell (PBSC) collections after taxol, cyclophosphamide and recombinant human granulocyte-colony-stimulating factor (rhG-CSF) J Clin Oncol 1995 13: 1714–1719
Demirer T, Buckner CD, Bensinger WI et al. Optimization of peripheral blood stem cell mobilization Stem Cells 1996 14: 106–116
Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte-colony stimulating factor J Clin Oncol 1997 15: 684–690
Demirer T, Bensinger WI, Buckner CD . Peripheral blood stem cell mobilization for high-dose chemotherapy J Hematother 1999 8: 103–113
Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells following the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients Transfusion 1997 37: 896–903
Bensinger W, Singer J, Appelbaum FR et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte-stimulating factor Blood 1993 81: 3158–3163
Thomas ED, Storb R . Technique for human marrow grafting Blood 1970 36: 507–515
Buckner CD, Appelbaum FR, Thomas ED . Bone marrow and fetal liver. In: Karow AM Jr, Pegg DE (eds) Organ Preservation for Transplantation Marcel Dekker: New York 1981 pp355–375
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568
Hsi BP . The multiple sample up-and-down method in bioassay J Am Stat Assoc 1969 64: 147–162
Frei E III, Canellos GP . Dose: a critical factor in cancer chemotherapy Am J Med 1986 69: 585–599
Frei E III, Cucchi GA, Rosowsky A et al. Alkylating agents resistance: in vitro studies with human cell lines Proc Natl Acad Sci USA 1985 82: 2158–2162
Frei E III, Teicher B, Cucchi GA et al. Resistance to alkylating agents: basic studies and therapeutic implications. In: Wooley P III, Tew K (eds) Mechanism of Drug Resistance in Neoplastic Cells Academic Press: New York 1988 pp69–87
Hyrniuk WM . Relative dose intensity and the impact on design of clinical trials Semin Oncol 1987 14: 65–74
Broder LE, Tormey DC . Combination chemotherapy of carcinoma of the breast cancer Cancer Treat Rev 1974 1: 183–203
Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 1989 7: 1748
Weaver CH, Greco FA, Hainsworth J et al. A phase I–II study of high-dose melphalan, mitoxantrone and carboplatin with PBSC support in patients with advanced ovarian or breast carcinoma Bone Marrow Transplant 1997 20: 847–853
Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan, and thiotepa with autologous stem cell support in patients with refractory malignancies Bone Marrow Transplant 1994 14: 813–819
Srivastava A, Bradstock KF, Szer J et al. Busulfan and melphalan prior to autologous bone marrow transplantation Bone Marrow Transplant 1993 12: 323–329
Schiffman K, Buckner CD, Maziarz R et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease Biol Blood Marrow Transplant 1997 3: 261–266
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Demirer, T., lhan, O., Mandel, N. et al. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 25, 697–703 (2000). https://doi.org/10.1038/sj.bmt.1702239
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702239
Keywords
This article is cited by
-
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences
Clinical and Translational Oncology (2013)
-
High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma – a retrospective evaluation
Bone Marrow Transplantation (2004)
-
High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation
Bone Marrow Transplantation (2003)
-
The effect of post-transplant spironolactone on daily potassium requirements in patients undergoing autologous stem cell transplantation
Bone Marrow Transplantation (2002)